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Abstract
Background: Angiogenesis is important in the growth and metastasis of various kinds of solid tumors, including
gastric cancers. The angiogenic process is triggered by several key growth factors, including vascular endothelial
growth factor (VEGF)-A and platelet-derived growth factor (PDGF)-B, that are secreted by tumors. Our aim was to
define: i) the expression pattern of VEGF-A and PDGF-B in tumor cells and the activation of PDGF receptor
(PDGFR)-b tyrosine kinase in stromal cells of human gastric adenocarcinomas; and ii) the relationship between
VEGF-A and PDGF-B expression and microvessel density (MVD), to determine if there is a rationale for a new
therapeutic strategy.
Methods: A series of 109 gastric adenocarcinoma cases that had undergone surgical resection was examined
immunohistochemically using antibodies against VEGF-A, PDGF-B, and CD34, followed by further examination of
PDGFR-b phosphorylation by immunoblotting analysis.
Results: MVD was higher in diffuse-type than intestinal-type cancers (p < 0.001). VEGF-A overexpression correlated
to PDGF-B overexpression in both the intestinal-type (p < 0.005) and diffuse-type (p < 0.0001) groups, indicating
that VEGF-A and PDGF-B are secreted simultaneously in the same tumor, and may thus play important roles
together in angiogenesis. However, several differences between intestinal-type and diffuse-type cancers were
observed. In the diffuse-type cancer group, higher MVD was related to the PDGF-B proportion (p < 0.05) and VEGF-
A overexpression (p < 0.05), but not to PDGF-B overexpression or the VEGF-A proportion. On the other hand, in
the intestinal-type cancer group, higher MVD was correlated to overexpression (p < 0.005), intensity (p < 0.05), and
proportion (p < 0.05) of PDGF-B, but not of VEGF-A. In addition, phosphorylation of PDGFR-b was correlated with
depth of cancer invasion at statistically significant level.
Conclusions: Our results indicate that PDGF-B, which is involved in the maintenance of microvessels, plays a more
important role in angiogenesis in intestinal-type gastric carcinomas than VEGF-A, which plays a key role mainly in
the initiation of new blood vessel formation. In contrast, VEGF-A has a critical role for angiogenesis more in diffuse-
type cancers, but less in those of intestinal type. Thus, a therapy targeting the PDGF-B signaling pathway could be
effective for intestinal-type gastric carcinoma, whereas targeting VEGF-A or both VEGF-A and PDGF-B signaling
pathways could be effective for diffuse-type gastric carcinomas.
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Over at least the past five decades, the mortality asso-
ciated with gastric cancer has decreased markedly in
most areas of the world [1,2]. However, gastric cancer
remains one of the most common human malignancies
worldwide [3]. The overall prognosis of gastric cancers
still remains unsatisfactory, although recent surgical and
chemotherapeutic interventions prolong survival of
patients in advanced stages [2]. Thus, improvement of
gastric cancer therapy will depend on early detection
and novel therapeutic approaches. One of the potentially
useful approaches is to inhibit tumor angiogenesis. In an
attempt to precisely evaluate angiogenesis and its inhibi-
tion, the degree of tumor angiogenesis has been esti-
mated by microvessel density (MVD). MVD, measured
by the hot spot method, is a valuable prognostic indica-
tor for a wide range of tumor types [4-6]. Previous stu-
dies showed that the angiogenic process is triggered by
several key growth factors that are secreted by the
tumor [7,8]. Among them, vascular endothelial growth
factor (VEGF)-A and platelet-derived growth factor
(PDGF)-B are the most studied [7,9-13]. It has been
demonstrated that these two growth factors participate
in the angiogenic process, and that VEGF-A plays a key
role mainly in the initiation of the formation of new
blood vessels, whereas PDGF-B is involved in the main-
tenance of microvessels and recruitment of pericytes [7].
These observations prompted an interest in designing
strategies to suppress the functions of VEGF-A and
PDGF-B, with the ultimate goal of inhibiting angiogen-
esis and starving tumors. These strategies include inhibi-
tion of the binding of VEGF-A and PDGF-B to their
respective receptors using antibodies against the growth
factors. One of these, bevacizumab (Avastin), which tar-
gets VEGF-A, has recently been approved for clinical
use in patients with metastatic colorectal cancer, as well
as non-small cell lung cancer [14,15]. Another approach
has involved the development of inhibitors of the tyro-
sine kinase activities of the PDGF-B and VEGF-A recep-
tors, which suppress the downstream signal
transduction pathways triggered by these growth factors
[15,16]. Most of these agents mimic the structure of
ATP, and some are potent antitumor agents that are
presently in clinical trials. However, none has yet been
approved for gastric cancers [17].
Previous reports focused on the role of VEGF-A in
gastric carcinomas and demonstrated that positive
immunohistochemical staining for VEGF-A correlates
with lymph node metastasis, depth of invasion, and vas-
cular invasion, suggesting that VEGF-A might be a use-
ful biomarker of tumor aggressiveness [18-21]. However,
other reports found no significant association between
VEGF-A expression and disease progression or patient
overall survival [22,23], or that VEGF-A expression was
more common in tumors without serosal invasion [24].
Furthermore, several reports showed higher VEGF-A
expression in intestinal-type than diffuse-type gastric
adenocarcinoma [22,25], whereas another study reported
that VEGF-A expression was not related to histological
type of gastric cancers [26]. Thus, the role of VEGF-A
in gastric carcinomas remains controversial.
A few reports have focused on the expression of
PDGF isoforms or their receptors in gastric adenocarci-
nomas [27-29]. However, the role of the PDGF-B signal
pathway in gastric carcinoma has not yet been
explained.
Our aim was to define: i) the expression pattern of
PDGF-B and VEGF-A in tumor cells and activation of
PDGFR-b tyrosine kinases in stromal cells of human
gastric adenocarcinoma; and ii) the relationship between
VEGF-A and PDGF-B expression and MVD, to deter-
mine whether there is a rationale for a new therapeutic
strategy.
Methods
Tissue samples
A total of 109 cases of gastric cancers obtained from
consecutive surgeries performed at the Department of
Surgery, Kanazawa University, between 2003 and 2009
were examined (Table 1). The patients included 69 male
and 40 female patients, with a mean age of 65.3 years
(range, 26-85 years). The condition of the patients was
assessed according to the system for staging primary
tumor/regional lymph nodes/distant metastasis (TNM)
described in the AJCC Cancer Staging Manual [30].
Tumors penetrating serosa or involved adjacent struc-
tures were observed in 44 patients (40.4%). Seventy five
patients (68.8%) had lymph node metastases. According
to Lauren’s criteria [31], the specimens were classified
into 63 intestinal-type and 46 diffuse-type adenocarcino-
mas. Thirty eight patients underwent total gastrectomy
and 71 patients underwent partial resection for their
cancers. D2 or more extended lymph node dissection
was conducted for 96 patients (88.0%). All cancers were
resected (no residual tumor, R-category 0) for 72
patients (66.1%). None of the patients had received any
preoperative treatments, including neoadjuvant therapy.
This laboratory study was approved by the Institutional
Review Board at the Kanazawa University, and written
informed consent was obtained from all patients.
Immunohistochemical staining
The Universal Immuno-Enzyme Polymer method
(Nichirei simple staining) was used. Tissue samples of
the investigated patients were obtained from the Pathol-
ogy Department of our university. The most invasive
areas of the carcinoma were selected; formalin-fixed and
paraffin-embedded blocks of those were cut 3-μm-thick
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stained with 0.02% diaminobenzidine (DAB) solution,
followed by counterstaining with hematoxylin. Primary
antibodies used were a mouse monoclonal immunoglo-
bulin (Ig) G specific for PDGF-B (PGF007, monoclonal;
Mochida; dilution 1:1000), CD34 (monoclonal, Dako,
ready-to-use), a-smooth muscle actin (SMA) (clone
1A4, monoclonal, Dako, ready-to-use), HIF-1a (clone
H1a 67, monoclonal, Novus Biologicals, dilution 1:50)
and NG2 (monoclonal, Abcam, dilution 1:100), rabbit
polyclonal IgG specific for VEGF (polyclonal, Lab
Vision; 1:100) and rabbit monoclonal IgG specific for
PDGFR-b (rabbit monoclonal; Cell Signaling Technol-
ogy; 1:2000). Histofine Simple Stain Max PO (Multi)
was used as a secondary antibody (Nichirei).
Staining analysis
For VEGF-A and PDGF-B assessment, the staining
intensity and the proportion of stained tumor cells were
analyzed, since it has been a consensus that both vari-
ables should be quantitatively analyzed to evaluate the
expression level of growth factors in correlation with
angiogenesis within the tumor nodule [20,24]. Staining
was considered immunoreactive when brown granules
were identified in the cytoplasm or nucleus of tumor
cells [24,27]. According to one of the established meth-
ods [20,24], staining intensity was scored as 0 (none), 1+
(weak), 2+ (moderate), or 3+ (strong). The proportion
of positively stained tumor cells in lesions was scored as
0 (0%), 1 (1%-25%), 2 (26-50%), 3 (51-75%), or 4 (76%-
100%). When the sum of the two scores was less than 4,
the section was considered negative, whereas 4 or more
was considered positive for overexpression of VEGF-A
or PDGF-B; the average values for both were between 3
and 4 (3.7 for PDGF-B and 3.3 for VEGF-A).
To assess tumor angiogenesis, MVD was determined
by immunohistochemical staining of CD34. The gener-
ally accepted criteria for determining a vessel profile
[5,6] were used, including any stained endothelial cell or
endothelial cell cluster that was separate from adjacent
microvessels. Vessel lumens were not required for iden-
tifying a structure as a microvessel. Microvessels in
necrotic or sclerotic areas within a tumor and immedi-
ately adjacent areas of unaffected gastric tissue were not
considered in vessel evaluations. The amount of immu-
nohistochemically highlighted microvessel profiles was
subjectively categorized by MVD scores 1-3. Two obser-
vers performed the vascular scoring by scanning the
tumor section at low magnifications, using ×4 and ×10
objective lens, thereby finding three separately located
tumor areas, where the highest number of discrete
microvessels was stained (hot-spots). Each hot-spot area
was equivalent to a high power field with a ×25 objec-
tive lens and a field diameter of 0.50 mm. The vascular
grading is both influenced by the number of vessel pro-
files in the initial scanning for hot-spots and by the area
of the vessel profiles within the hot-spots in the succes-
sive grading process. Thus, given an area with high
angiogenesis activity by many microvessels, the vessel
profiles with a larger cross-sectional area or perimeter
contribute more to a high vascular grade. Score 1 (low
angiogenesis) was registered when the combined area of
the three hotspots contained a low amount of endothe-
lial-stained microvessel profiles. Score 1 was typically
assigned to tumors without any actual hot-spots. Score
2 (intermediate angiogenesis) was assigned when the
combined area of the three hot-spots contained a mod-
erate amount of vessel profiles. Score 2 was typically
assigned to tumors with one very vascular hot-spot or
with two hot-spots with only a low amount of microves-
sels. Score 3 (high angiogenesis) was registered when
the combined area of the three hot-spots had numerous
vessel profiles with a large average area or perimeter of
Table 1 Clinicopathological features
No. of patients %
Total number of patients 109
Sex
Male 69 63.3
Female 40 36.7
Age
Mean (Range) 65.3 (26-85)
Lauren classification
Intestinal 63 57.8
Diffuse 46 42.2
T stage
T1 7 6.4
T2 58 53.2
T3 35 32.1
T4 9 8.3
N stage
N0 34 31.2
N1 55 50.5
N2 14 12.8
N3 6 5.5
Extent of surgical resection
gastrectomy 38 34.9
partial resection 71 65.1
Extent of lymphadenectomy
D0 4 3.7
D1 8 7.3
D2 91 83.5
D3 5 4.6
Residual tumor status (R-category)
R0 72 66.1
R1 27 24.8
R2 10 9.2
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Page 3 of 10vessel profiles. The determination of angiogenesis was
performed without knowledge of the prognostic out-
come. About one minute was used for vascular grading
per tumor.
The number and location of pericytes were deter-
mined by combined assessment of immunohistochem-
ical results against PDGFR-b, aSMA and NG2.
According to a previous report [22], a positive value
for HIF-1a was recorded when nuclear staining was
observed in >1% of cancer cells, whereas cytoplasmic
staining was not counted.
Assessment of the staining was scored independently
by two investigators (S.S. and A.O.) without knowledge
of the clinicopathological findings. The allocation of
tumors and scoring of staining by the two investigators
was similar. In cases of disagreement, slides were reeval-
uated and discussed until consensus was achieved.
Immunoblotting analysis
Lysates were prepared from these fresh tissues as
described [32], and immunoblotting analysis was per-
formed. Equal amounts (30 μg of lysates) of protein
were used for blotting with anti-PDGF-B (PDGF-BB,
Abcam; 1:200) and anti-p-PDGFR-b (Tyr751, Cell Sig-
naling Technology; 1:2000) antibodies. Blotting with
anti-b-actin (Ambion; 1:5000) and anti-PDGFR-b (rabbit
monoclonal; Cell Signaling Technology; 1:2000) antibo-
dies was also performed as loading controls.
Expression levels were quantified by densitometric
analysis with Chemi Imager 5500 (AlphaInotech). Levels
of PDGF-B or p-PDGFR-b were standardized by b-actin
or PDGFR, respectively, assigned an arbitrary level of
“1.0"; the expression signal relative to these was indi-
cated as the “expression value” for each protein. The
“protein index” of PDGF-B or p-PDGFR-b was obtained
by dividing the “expression value” in tumor tissue by
that in non-neoplastic tissue. In this study, expression
signal was interpreted as “overexpressed” (for PDGF-B
expression) or “activated” (for p-PDGFR-b) i) when the
“protein index” was higher than 1.5 or 1.0, respectively,
or ii) when protein expression was barely detectable in
the paired non-neoplastic tissue [32,33].
Statistical analysis
StatView software (version 5.0; Abacus Concepts) was
used for the data analysis. Clinicopathological variables,
as well as expression of VEGF-A and PDGF-B and
MVD, were analyzed. The correlations between VEGF-A
and PDGF-B expressions, MVD, and the other variables
were assessed with the c
2 and Fisher’s exact tests. The
Spearman test was performed to evaluate rank data. Sur-
vival durations were calculated via the Kaplan-Meier
method. The log-rank test was employed to compare
cumulative survival in the patient groups. Statistical
significance was defined as a probability value less than
0.05, in all tests.
Agreement among observers for the interpretation of
IHC specimens was qualified by kappa () statistics [34].
In accordance with the criteria of Landis and Koch [35],
the -values were divided into several scales to evaluate
the strength of agreement:  < 0.00, poor; 0.00< <0 . 2 0 ,
slight; 0.21< < 0.40, fair; 0.41< < 0.60, moderate;
0.61< < 0.80, substantial; 0.81< < 1.00, nearly perfect.
Results
Immunohistochemical analyses
MVD
Of the 63 patients with intestinal-type cancers, 15
(23.8%) had an MVD score 1 (Figure 1a), 33 (52.3%)
score 2 (Figure 1b), and 15 (23.8%) score 3 (Figure 1c),
whereas of the 46 patients with diffuse-type cancers,
3 (6.5%) had score 1, 19 (41.3%) score 2, and 24 (52.1%)
score 3. Overall interobserver agreement was nearly
perfect ( = 0.91; 95% confidence interval, 0.87-0.97).
A higher MVD score was observed in the diffuse-type
(mean 2.46) than intestinal-type (mean 2.00) cancers
(p < 0.001).
Expression of PDGF-B and VEGF-A
Immunoreactivity for VEGF-A was detected predomi-
nantly in the cytoplasm of the carcinoma cells (Fig-
ure 2). Immunoreactivity for PDGF-B was present
diffusely or focally in the cytoplasm and nucleus of
malignant cells, of some inflammatory cells, and of
cells in the surrounding stroma (Figure 2), but not in
normal epithelial cells. According to the presence/
Figure 1 Microvessel density staining for CD34 in intestinal
type gastric cancer. A hot-spot with low angiogenesis (a) contains
fewer positive staining (arrow) than those of hot spot with
intermediate (b) or high (c) angiogenesis. The vascular grade of the
tumor would be intermediate or grade 2, if the three hot-spots
were from the same tumor.
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Page 4 of 10absence in overexpression of VEGF and PDGF, as
measured by a summation score of staining intensity
and proportion of positive staining cells, cases were
classified to 4 types: Type 1, with overexpression of
both VEGF-A and PDGF-B (36 cases); Type 2, with
overexpression of VEGF-A but not PDGF-B (9 cases);
Type 3, with overexpression of PDGF-B but not
VEGF-B (19 cases); Type 4, without VEGF-A or
PDGF-B overexpression (45 cases). Immunohisto-
chemical analyses of representative cases in type1-4
are shown in Figure 2.
Relationship between overexpression of PDGF-B and
VEGF-A
In intestinal-type cancers, overexpression of PDGF-B
or VEGF-A was observed in 50% (31 cases) or 41%
(26 cases) of the 63 cases, respectively (Table 2).
Overall interobserver agreement was nearly perfect
( = 0.89; 95% confidence interval, 0.85-0.96). Overex-
pression of PDGF-B was more common in cases with
overexpression of VEGF-A than in those without
VEGF-A overexpression (p < 0.005, Table 2). In
diffuse-type cancers, overexpression of PDGF-B or
VEGF-A was observed in 52% (24 cases) or 41%
(19 cases) of the 46 cases, respectively (Table 2).
Overexpression of PDGF-B correlated with that of
VEGF-A (p < 0.0001, Table 2).
Impact of VEGF-A and PDGF-B overexpression on
angiogenesis
Analysis of the data according to histological type of
carcinomas (intestinal vs. diffuse) showed some signifi-
cant correlations that were not present when consider-
ing the global patient population.
For intestinal-type cancers, the following correlations
were found. A higher MVD score correlated with pro-
portion (p < 0.05), intensity (p < 0.05), and overexpres-
s i o n( p<0 . 0 0 5 ,T a b l e3 )o fP D G F - B .H o w e v e r ,t h e
MVD score did not correlate with proportion (p = 0.67),
Figure 2 Immunohistochemical staining of VEGF-A, PDGF-B, PDGFR-b and CD34 with hematoxylin and eosin staining (HE) in
representative tissue sections obtained from human gastric carcinoma. According to the presence/absence in overexpression of VEGF and
PDGF, as measured by a summation score of staining intensity and proportion of positive staining cells for VEGF-A and PDGF-B, cases were
classified to 4 types: Type1, VEGF-A+/PDGF-B+; Type2, VEGF-A+PDGF-B-; Type3, VEGF-A-/PDGF-B+; Type4, VEGF-A-/PDGF-B-. Immunoreactivity for
VEGF-A is detected predominantly in the cytoplasm of the carcinoma cells (arrow), whereas PDGF-B reactivity is strong in the nuclei and weak in
the cytoplasm (arrow head). Staining for PDGFR-b was seen in many pericytes (outline arrow) of PDGF-B overexpressing carcinomas, implying
that PDGF produced by cancer cells caused increased pericyte coverage around vessels.
Table 2 Relationships between PDGF overexpression or
VEGF overexpression
VEGF over expression
< intestinal type > (+) (-)
PDGF overexpression
(+) 19 12 p < 0.005
(-) 7 25
total 26 37
< diffuse type >
PDGF overexpression
(+) 17 7 p < 0.0001
(-) 2 20
total 19 27
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Page 5 of 10intensity (p = 0.45), or overexpression (p = 0.72,
Table 3) of VEGF-A. For diffuse-type cancers, a higher
MVD score was correlated with proportion (p < 0.05) of
PDGF-B, but not with intensity (p = 0.67) or overex-
pression (p = 0.15, Table 3) of PDGF-B staining.
However, with regard to VEGF-A, the MVD score was
correlated with overexpression (p < 0.05, Table 3), but
not with proportion (p = 0.066) or staining intensity
(p = 0.72).
Statistical analysis
In diffuse-type cancers, lymph node metastasis was cor-
related with a higher MVD score (p < 0.05), whereas the
depth of invasion was not correlated with other factors.
In intestinal-type cancers, prognostic factors, including
lymph node metastasis and depth of invasion, did not
correlate with PDGF-B and VEGF-A overexpression or
the MVD score.
Location of pericytes
To determine the number and location of pericytes,
immunohistochemistry (IHC) was done with specimens
using antibodies for aSMA, PDGFR-b and NG2. Positive
stainings for PDGFR-b and aSMA were seen predomi-
nantly in the membrane and cytoplasm of the stromal
cells, including pericytes, but not in carcinoma cells in
similar patterns, although positive staining for NG2 was
observed in only a few stromal cells. In detail, PDGFR-b
staining was seen more selectively in cells around ves-
sels, whereas aSMA staining was observed also in many
other stromal cells. These findings showed that PDGFR-
b had high specificity for recognizing pericytes. Further-
more, staining for PDGFR-b was seen in many pericytes
in PDGF-B overexpressing carcinomas, implying that
PDGF-B produced by cancer cells caused increased peri-
cyte coverage around vessels, whereas faint staining was
also seen in pericytes of carcinomas without PDGF-B
overexpression (Figure 2).
Expression of HIF-1a
Cytoplasmic staining for HIF-1a was observed in many
cancer cells, whereas nuclear staining was observed in
only a part of them. The latter was located in both the
center and the periphery of cancers and the location was
not clearly related with staining for VEGF-A or PDGF-B.
Prognostic significance of VEGF-A and PDGF-B
overexpression and MVD
The median follow-up duration was 31 months (range,
1-85.4 months) after operation. The hospital mortality
and postoperative morbidity were 0% and 4.5%, respec-
tively. Recurrence of carcinomas were observed in 31
cases. No significant association was observed between
s u r v i v a la n dV E G F - A( p=0 . 5 0 )o rP D G F - B( p=0 . 9 1 )
overexpression or MVD (p = 0.73).
Immunoblotting analysis
To evaluate the relative levels of expression of PDGF-B
or phosphorylation of PDGFR-b in tissue samples, and
to evaluate their correlation with immunohistochemical
results, immunoblotting was performed. The results
from the 35 cases of fresh tissue specimens are pre-
sented in Table 4 and two representative tissue speci-
mens are shown in Figure 3.
Table 4 Relationships between phosphorylation of PDGFR-b and PDGF-B overexpression
WB PDGFR-b phosphorylation WB PDGF-B overexpression IHC PDGF-B overexpression No. of cases
++ + 5
++ - 4
+- + 3
+- - 1
-+ + 1 1
-+ - 8
-- + 1
-- - 2
Abbreviations: IHC, immunohistochemistry; WB, western blot.
Table 3 Relationships between MVD and overexpression
of PDGF-B or VEGF-A
VEGF overexpression PDGF overexpression
(+) (-) (+) (-)
<intestinal type>
MVD *p = 0.72 **p < 0.005
17 8 4 1 1
21 1 2 2 1 5 1 8
38 7 1 2 3
<diffuse type>
MVD *p < 0.05 **p = 0.15
10 3 0 3
2 6 13 10 9
31 3 1 1 1 4 1 0
total 19 27 24 22
*p, VEGF-A(+) group vs VEGF-A(-) group.
**p, PDGF-B(+) group vs. PDGF-B(-) group.
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ples obtained from both tumor and normal tissues,
upon analysis by SDS-gel electrophoresis under non-
reducing conditions followed by immunoblotting. Of the
35 cases, 28 (80%) showed PDGF-B overexpression
(more than 1.5 times of those of normal tissue). In 12 of
these 28 cases, PDGF-B overexpression was detected by
immunoblotting, but not by IHC, while in 4 cases,
PDGF-B overexpression was detected by IHC, but not
by immunoblotting.
PDGFR was detectable as a 190-kD protein in 17 sam-
ples obtained from both tumor and normal tissues. Acti-
vation of PDGFR-b in tumor, relative to normal tissue,
was noted in 13 (37%) of the 35 cases. Among the 13
cases with activation of PDGFR, PDGF-B overexpression
was detected by IHC or immunoblotting in 9 or 8 cases,
respectively. No significant correlations were seen
between activation of PDGFR-b and overexpression of
PDGF-B detected by IHC or immunoblotting (p = 0.70
and p = 0.23, respectively).
Relationship between activation of PDGFR-b and
angiogenesis
There was no clear relationship between activation of
PDGFR-b and angiogenesis in tumors (p = 0.55). Of the
13 tumors with PDGFR-b activation, 12 (92%) had a
MVD score of 2 or 3, whereas in the 22 tumors without
PDGFR activation, 18 (82%) had a MVD score of 2 or 3.
Relationship between activation of PDGFR-b and depth of
invasion
Among 20 cases with PDGF-B overexpression, detected
by IHC, all 8 cases with activation of PDGFR-b, detected
by immunoblotting, penetrated into the subserosal layer,
whereas only 6 of 12 cases without activation of
PDGFR-b invaded into the subserosal layer (p < 0.05).
Thus, phosphorylation of PDGFR-b was correlated with
depth of cancer invasion at statistically significant level.
Discussion
There has been much literature describing the overex-
pression of VEGF-A in gastric cancer, with frequencies
ranging from 36% to 76% [18-22,26,27,36], consistent
with the 43.1% found in the present study.
Using IHC, previous studies showed that VEGF-A
expression was seen more frequently in intestinal-type
than in diffuse-type cancers [18,22,25]. In addition,
using an enzyme immunoassay in gastric cancers and
surrounding non-cancerous mucosa, another study
showed that VEGF-A expression was significantly higher
in intestinal-type than diffuse-type gastric cancer [37].
However, other studies reported that VEGF-A expres-
sion was not related to histological type of gastric cancer
[24,26]. In the present study, no difference between the
intestinal-type and diffuse-type cases was seen with
regard to the frequency of VEGF-A overexpression
(41.3% and 41.3%, respectively; p = 0.997) (Table 2).
A significant correlation between MVD score and
VEGF-A expression has been reported in certain pre-
vious studies [18,20,27], but not in others [37]. The
result of the present study is consistent with the latter
(p = 0.14). However, analysis of the data according to
histological type of carcinoma (intestinal vs. diffuse),
VEGF-A overexpression, as measured by a summation
score of staining intensity and proportion of positive
staining cells for VEGF-A, was related with higher
MVD in diffuse-type gastric cancers (p < 0.05), but not
in intestinal-type cancers (p = 0.72) (Table 3). This
result suggests that the ratio of diffuse-type cases rela-
tive to total cases may have influenced the relationship
b e t w e e nV E G F - Ae x p r e s s i o na n dM V Ds c o r ei nt h e
statistical analysis as in previous studies if all samples
were analyzed as a whole. In the present study, diffuse-
type cases represented 35% of male cases and 55% of
female cases, which are close to the natural incidence
[38].
In a previous study, it was demonstrated that the
positive immunostaining rates of VEGF-A correlated
with lymph node metastasis, depth of invasion, and
vascular invasion, suggesting that this protein might be
a useful biomarker of tumor aggressiveness [20]. How-
ever, other studies showed that high VEGF-A and
M V Dw e r em o r ec o m m o ni nt u m o r sw i t h o u ts e r o s a l
invasion [24], and no significant correlation between
VEGF-A expression and MVD score, patient survival,
and clinicopathological factors was found [22,37]. Con-
sistent with the latter studies, in the present study,
VEGF-A overexpression was not correlated with lymph
node metastases and depth of invasion and no associa-
tion was found between patient survival and VEGF-A
expression or MVD. However, phosphorylation of
PDGFR-b was significantly correlated with depth of
cancer invasion.
Figure 3 Protein levels of PDGF-B, PDGFR-b, and p-PDGFR-b
evaluated by immunoblotting analysis in representative two
cases (G1, PDGF-B overexpression -/p-PDGFR-b-; G27, PDGF-B
overexpression +/p-PDGFR-b +) of tumor and paired normal
tissue. Porcine aortic endothelial cells expressing PDGFR-b (PAE-b),
was stimulated by PDGF-B and used as positive control for
phosphorylation of PDGFR-b. N, normal tissue; C, cancer tissue.
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PDGF isoforms or their receptors in gastric adenocarci-
nomas [27-29] and thus, the role of the PDGF-B signal
pathway in gastric carcinoma has not yet been
explained. In the present study, IHC analysis showed
that PDGFR-b staining had high specificity for recogniz-
ing pericytes, compared to NG2 and aSMA. This result
was consistent with the result in one recent study show-
ing that PDGFR-b expression was restricted to stromal
pericytes [28]. Moreover, in the cases with carcinoma
overexpressing PDGF-B,m o r ei n t e n s eP D G F R - b stain-
ing was seen in many pericytes than in those without
PDGF-B overexpression. This result may suggest that
PDGF-B, produced by cancer cells, cause increased peri-
cyte coverage around vessels, and upregulation of
PDGFR-b expression.
On the other hand, PDGF-B staining was not
restricted in cancer cells and also in some inflammatory
and stromal cells. In some cases, there was a discre-
pancy of the results obtained by immunoblotting com-
pared to IHC (Table 4). One of the reasons for this may
be that immunoblotting provides data of an average of
expression levels of PDGF-B produced not only by can-
cer cells but also by inflammatory and stromal cells, and
not a focal expression in cancer cells as evaluated with
IHC.
Overall, our thorough study of the correlations of
PDGF-B and VEGF-A with angiogenesis revealed several
new findings. First, PDGF-B overexpression was seen in
50% of all cases and correlated with a higher MVD
score. These results are almost consistent with those
reported previously, showing PDGF-B expression in 41%
of cases and its correlation with a higher MVD score
[27]. Second, PDGF-B overexpression correlated with
VEGF-A overexpression in intestinal-type and diffuse-
type cancers (Table 2). These results suggest that
PDGF-B and VEGF-A were secreted simultaneously in
the same tumor and cooperated in the stimulation of
angiogenesis. Finally, as novel findings, several differ-
ences between intestinal-type and diffuse-type cancers
w e r eo b s e r v e d .I nt h ed i f f u s e - t y p eg r o u p ,t h eM V D
score was related with PDGF-B proportion and VEGF-A
overexpression, but not with PDGF-B overexpression
(Table 3) or VEGF-A proportion. On the other hand, in
intestinal-type cancers, MVD score correlated with over-
expression (Table 3), intensity, and proportion of
PDGF-B, whereas no correlation was observed between
a higher MVD score and overexpression, intensity, and
proportion of VEGF-A.
Collectively, these results suggest that: i) VEGF-A is
an important factor for angiogenesis, critically involved
more in diffuse-type, but less in intestinal-type cancers;
and ii) that PDGF-B plays an important role not only in
intestinal-type but also diffuse-type cancers. Therefore,
therapies targeting the PDGF-B signaling pathway could
be effective for intestinal-type cancers, whereas therapies
targeting VEGF-A or both VEGF-A and PDGF-B signal-
ing pathways could be effective for diffuse-type gastric
cancers. Recently, many inhibitors have been developed
against PDGF-B, VEGF-A, and their cognate receptors.
An inhibitor targeting VEGFRs in endothelial cells
(SU5416) has been demonstrated to be effective against
early-stage angiogenic lesions [16]. In contrast, a kinase
inhibitor selective for PDGFRs (SU6668) was shown to
block growth of end-stage tumors, eliciting detachment
of pericytes and disruption of tumor vascularity [16].
Another study showed that treatment with the selective
PDGF receptor kinase inhibitor, STI571 (imatinib),
decreased interstitial hypertension and increased drug
uptake and therapeutic effectiveness of cancer che-
motherapy [39]. Thus, neoadjuvant therapy using these
drugs may decrease tumor size, reduce the stage or
extent of tumor before attempting surgical control, or
improve the results of surgery, although no association
was found between survival and overexpression of
VEGF-A or PDGF-B in the current study. Furthermore,
the result may help to stratify patients with diffuse or
intestinal types of gastric carcinomas, before treatment
or after the operation at the time of relapse, for treat-
ment with kinase inhibitors, targeting PDGF-B or
VEGF-A receptors. This kind of tailored preoperative
regimens may enable a limited surgical intervention,
such as endoscopic submucosal dissection or partial gas-
trectomy, and avoid needlessly treating the patients by
total gastrectomy.
Conclusions
PDGF-B plays a more important role in angiogenesis in
intestinal-type gastric carcinomas than VEGF-A. In con-
trast, VEGF-A has a more critical role for angiogenesis
in diffuse-type cancers. Thus, a therapy targeting the
PDGF-B signaling pathway could be effective for intest-
inal-type gastric carcinoma, whereas targeting VEGF-A
or both VEGF-A and PDGF-B signaling pathways could
be effective for diffuse-type gastric carcinomas.
Abbreviation
VEGF: vascular endothelial growth factor; PDGF: platelet-derived growth
factor; MVD: microvessel density; PDGFR: platelet-derived growth factor
receptor; IHC: immunohistochemistry.
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